Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

pathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

About Schering-Plough

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... primary and metastatic cancers to the liver, today provided an update on recent corporate developments.   , ... , , ... ... ... ...
(Date:3/11/2010)... Zimmer Holdings, Inc. (NYSE: ... care, will celebrate the 25th anniversary of the ... this year.  The Natural Knee ... anatomically designed implants used in more than 400,000 ... the Natural Knee system to be ...
(Date:3/11/2010)... March 11 Watson Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) approval of ... a new twice-yearly formulation of TRELSTAR®, a proven, ... cancer. With an anticipated May launch, TRELSTAR® 22.5 ... (IM) GnRH agonist available for the palliative treatment ...
Breaking Medicine Technology:Delcath Systems Provides Update on Corporate Developments 2Delcath Systems Provides Update on Corporate Developments 3Delcath Systems Provides Update on Corporate Developments 4Delcath Systems Provides Update on Corporate Developments 5Delcath Systems Provides Update on Corporate Developments 6Delcath Systems Provides Update on Corporate Developments 7Delcath Systems Provides Update on Corporate Developments 8Delcath Systems Provides Update on Corporate Developments 9Delcath Systems Provides Update on Corporate Developments 10Delcath Systems Provides Update on Corporate Developments 11Delcath Systems Provides Update on Corporate Developments 12Zimmer Natural Knee Celebrates 25 Years of Excellence 2Zimmer Natural Knee Celebrates 25 Years of Excellence 3Zimmer Natural Knee Celebrates 25 Years of Excellence 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 1Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 2Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 3Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 4Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 5Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 6Reportlinker Adds Childrens Food and Drinks in Europe A Guide to Markets Products and Innovation 2nd Edition 61953 7Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 1Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 2Reportlinker Adds Anesthesia Disposables A World Market Review 6471 1Reportlinker Adds Anesthesia Disposables A World Market Review 6471 2Reportlinker Adds Anesthesia Disposables A World Market Review 6471 3Reportlinker Adds Anesthesia Disposables A World Market Review 6471 4Reportlinker Adds Anesthesia Disposables A World Market Review 6471 5Reportlinker Adds Anesthesia Disposables A World Market Review 6471 6Reportlinker Adds Anesthesia Disposables A World Market Review 6471 7Reportlinker Adds Anesthesia Disposables A World Market Review 6471 8Reportlinker Adds Anesthesia Disposables A World Market Review 6471 9Reportlinker Adds Anesthesia Disposables A World Market Review 6471 10Reportlinker Adds Anesthesia Disposables A World Market Review 6471 11Reportlinker Adds Anesthesia Disposables A World Market Review 6471 12Reportlinker Adds Anesthesia Disposables A World Market Review 6471 13Reportlinker Adds Anesthesia Disposables A World Market Review 6471 14Reportlinker Adds Anesthesia Disposables A World Market Review 6471 15Reportlinker Adds Anesthesia Disposables A World Market Review 6471 16Reportlinker Adds Anesthesia Disposables A World Market Review 6471 17Reportlinker Adds Anesthesia Disposables A World Market Review 6471 18Reportlinker Adds Anesthesia Disposables A World Market Review 6471 19Reportlinker Adds Anesthesia Disposables A World Market Review 6471 20Reportlinker Adds Anesthesia Disposables A World Market Review 6471 21Reportlinker Adds Anesthesia Disposables A World Market Review 6471 22Reportlinker Adds Anesthesia Disposables A World Market Review 6471 23Reportlinker Adds Anesthesia Disposables A World Market Review 6471 24Reportlinker Adds Anesthesia Disposables A World Market Review 6471 25Reportlinker Adds Anesthesia Disposables A World Market Review 6471 26
... who received,OrbusNeich,s pro-healing stent, the Genous Bio-engineered R ... than patients who,received Boston Scientific,s TAXUS or Johnson ... at Federico II University of,Naples in Naples, Italy. ... the XXVIII National Congress of the Italian Society ...
... Age, Becomes Squarer, Makes You Look Older, ASPS,Study Reveals, ... be giving away your age, and it has nothing ... study in January,s Plastic and,Reconstructive Surgery(R) (PRS), the official ... found that as we age, the,lower jaw continues to ...
Other Medicine Technology:OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial 2Looking Older? How Square is Your Jaw Line? 2
(Date:3/15/2010)... the Company,s participation at the Barclays Capital 2010 Global Healthcare Conference at the Loews Miami Hotel in Miami, Fla. to be held March ... ... ... ... Doug Schuling , ...
(Date:3/15/2010)... store today offering U.S. consumers the healthiest new green cleaning ... by a team of executives and engineers with decades of ... provides new products that clean the air, best-in-class green cleaning ... ... Austin, Texas (Vocus) March 15, 2010 -- ...
(Date:3/15/2010)... shows improvement in staff productivity and payroll processing time thus freeing ... out paper forms! , ... Schaumburg, IL (PRWEB) March ... improvement in staff productivity and payroll processing time thus freeing staff ... paper forms!, , , , ,The Hospice of Baton Rouge has ...
(Date:3/15/2010)... FRANCISCO , March 15 Quantros, a leading healthcare software and services provider of data management, decision support analytics, and ... monitoring. , ... , , ... ... ...
(Date:3/14/2010)... announced that is has reached the 1 million customer mark, meaning ... million customers nationwide. , ... (Vocus) March 14, 2010 ... million orders since its website launched in 1997. The first company ... largest online supplier of home health care products. Its diverse product ...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the Barclays Capital 2010 Global Healthcare Conference 2Health News:Genoptix Announces Participation at the Barclays Capital 2010 Global Healthcare Conference 3Health News:Oransi Opens Online Store Connecting Consumers with the Best New Green Cleaning Products 2Health News:Oransi Opens Online Store Connecting Consumers with the Best New Green Cleaning Products 3Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 2Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 3Health News:Hospice of Baton Rouge Selects CellTrak as a Good Steward of Time and Talent 4Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2
... LOGAN, Utah, Oct. 15 Facet Solutions, Inc. ... on the first cohort of,patients to receive its ... these patients at one year include a significant,decline ... function; and no,post-operative complications. Additionally, the first patient ...
... PCOP ), an innovator in the discovery and ... it has licensed from,Bristol-Myers Squibb (NYSE: BMY ... a lead compound in Phase 1 clinical development,and ... modulator, or SARM, which was designed to provide ...
... Toronto Stock Exchange Symbol: AKL, MONTREAL, Oct. ... drug development company focused on developing therapies for ... is undertaking a,public offering in the United States ... granted the underwriters a 30-day option to purchase ...
... published in the October 15 issue of the Journal ... well-tolerated in the treatment of excessive sleepiness associated with ... sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and ... study, authored by Thomas Roth, PhD, of the Henry ...
... published in the October 15 issue of the Journal ... Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure ... by James C. Spilsbury, PhD, of the Division of ... a subsample of 411 adolescents between 11-17 years of ...
... With school schedules now routine and,the initial excitement ... This might be a good time to re-evaluate menus ... http://www.newscom.com/cgi-bin/prnh/20071015/NYFNSL01 ) The following are suggestions from ... snacks for greater nutritional impact. Add a,handful of trail ...
Other Medicine News:Health News:Facet Solution's AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up 2Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 2Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 3Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 4Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 5Health News:AKELA Pharma Inc. announces U.S. public offering and proposed listing 2Health News:Study: Modafinil is effective in treating excessive sleepiness 2Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Fresh, Tasty - Healthy - Lunch and Snack Ideas 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... of plugs and allow precise control of liquid ... sorting. Colored graduations are enameled onto the glass. ... "To Deliver" its total capacity when the last ... L 8 350 mm Measur range: volume ...
Corning 7078 Calibrated"to deliver". multi-pack plugged capacity 5 mL...
... and O.R. staff work hard to protect ... intravasation. Manual methods are complicated, time-consuming, and ... II Fluid Management System for hysteroscopy, designed ... irrigation. It has been developed to provide ...
Medicine Products: